New drug cocktail may replace bone marrow transplant for some leukemia patients

NCT ID NCT07259707

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid a bone marrow transplant. About 25 participants will receive the treatment and be monitored for remission and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia, FLT3 internal tandem duplication

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA FIT PATIENTS FLT3 INTERNAL TANDEM DUPLICATION POSITIVE INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••